Neuroscience biopharmaceutical company Aprinoia Therapeutics has announced a phase II multicenter international study of a new PET tracer for detecting Alzheimer's disease based on tau deposits.
The study of tau PET tracer 18F-APN-1607 will examine tau deposition patterns of patients with mild cognitive impairment due to Alzheimer's disease and dementia due to Alzheimer's disease in comparison with healthy older adults.
The tracer is unique among other tau PET tracers since it can image rare tauopathies, according to the company. It could, therefore, prove useful in detecting tau distribution patterns across all tauopathies.
